Study of the Immune Response After Vaccination in Multiple Myeloma Patients
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Hematology, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 2/22/2019 |
| Start Date: | December 30, 2014 |
| End Date: | August 10, 2017 |
The Immune Response Following Vaccination in Multiple Myeloma Patients: A Prospective Pilot Study
This study will collect blood samples from healthy volunteers and volunteers with multiple
myeloma who are going to get the seasonal flu, pneumonia, haemophilus influenzae B (HIB),
and/or meningococcus vaccines.
The main goal of the study is to start to identify differences in the immune response between
multiple myeloma patients and people who don't have multiple myeloma. We hope this will
provide important information about the best way and time to vaccinate multiple myeloma
patients to flu, pneumonia, haemophilus influenzae B (HIB), and/or meningococcus .
myeloma who are going to get the seasonal flu, pneumonia, haemophilus influenzae B (HIB),
and/or meningococcus vaccines.
The main goal of the study is to start to identify differences in the immune response between
multiple myeloma patients and people who don't have multiple myeloma. We hope this will
provide important information about the best way and time to vaccinate multiple myeloma
patients to flu, pneumonia, haemophilus influenzae B (HIB), and/or meningococcus .
This study will consist of a prospective blood sample collection to gather baseline data to
confirm antibody protection from vaccines in the Aurora Health Care multiple myeloma (MM)
patients.
The overall goal of this study is to obtain a normative dataset for MM patients and non-MM
control populations as well as determining baseline IgG levels to seasonal influenza A,
influenza B, pneumococcal polysaccharide, and tetanus toxoid and confirmation of antibody
protection from vaccines with assays based upon WHO standards of detection.
This is part of a series of studies designed to provide important information about the best
way and time to vaccinate MM patients to flu, pneumonia, haemophilus influenzae B (HIB),
and/or meningococcus and to gather additional information about MM and immune function.
confirm antibody protection from vaccines in the Aurora Health Care multiple myeloma (MM)
patients.
The overall goal of this study is to obtain a normative dataset for MM patients and non-MM
control populations as well as determining baseline IgG levels to seasonal influenza A,
influenza B, pneumococcal polysaccharide, and tetanus toxoid and confirmation of antibody
protection from vaccines with assays based upon WHO standards of detection.
This is part of a series of studies designed to provide important information about the best
way and time to vaccinate MM patients to flu, pneumonia, haemophilus influenzae B (HIB),
and/or meningococcus and to gather additional information about MM and immune function.
Inclusion Criteria:
- 50 years old or over
- planning on getting the seasonal flu and/or pneumonia vaccine as part of normal care
- have multiple myeloma, or don't have multiple myeloma and want to serve as a health
control
Exclusion Criteria:
- do not meet inclusion criteria
We found this trial at
1
site
Milwaukee, Wisconsin 53215
Principal Investigator: Michael Thompson, MD, PhD
Phone: 414-778-4367
Click here to add this to my saved trials
